Multicenter, open, single-arm phase 3 studies were carried out in ten hospitals in Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK in patients with morbid obesity associated with pro-opiomelanocortin deficiency (POMC) or obesity due to leptin receptor deficiency (LEPR). This evidence concerns the gene POMC and morbid obesity.